

Fluorine-containing α -alkynyl amino esters and access to a new family of 3,4-dehydropoline analogues†

David Sémeril,^a Jérôme Le Nôtre,^a Christian Bruneau,^a Pierre H. Dixneuf,^{*a}
Alexey F. Kolomiets^b and Sergey N. Osipov^{*b}

^a Laboratoire d'Organométalliques et Catalyse: Chimie et Electrochimie Moléculaires (CNRS UMR 6509), Université de Rennes, Campus de Beaulieu, 35042 Rennes, France.
E-mail: pierre.dixneuf@univ-rennes1.fr

^b A N Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov str. 28, 117813 Moscow, V-334, GSP-1, Russia. E-mail: osipov@ineos.ac.ru

Received (in Montpellier, France) 6th September 2000, Accepted 11th October 2000
First published as an Advance Article on the web 8th December 2000


New α -alkynyl, α -CF₃ amino esters have been prepared from electrophilic imines and used to produce 3-alkenyl-3,4-dehydropoline derivatives, *via* enyne metathesis with the precatalyst [Ru=C=C=CPh₂(Cl)(PCy₃)(arene)]O₃SCF₃. These new conjugated fluorine-containing dienes are active substrates for the Diels–Alder reaction and lead to a new class of bicyclic amino esters.

α,α -Disubstituted α -amino acids constitute an important class of nonproteinogenic amino acids that has recently received a great deal of attention.¹ In particular, the incorporation of these compounds into peptides results in conformational restrictions and increased rigidity, leading to enhanced resistance towards protease enzymes and to the stabilisation of some secondary structures.² Moreover, such α -amino acids bearing an alkynyl or CF₃ group at the α -position irreversibly inhibit the action of various pyridoxal phosphate-dependant enzymes³ such as alanine racemases^{4a} or decarboxylases.^{4b} On the other hand, increasing interest in new proline derivatives is connected with the fact that proline is unique among the natural amino acids for its abilities to induce β -turns and initiate peptide folding of the α -helix.⁵ Due to these structurally important properties, proline is often regarded as the primary contributor to the biological activity of several proteins, as well as having a key role in biological recognition processes.⁵ Structurally modified prolines, especially those containing multiple C–C bonds, have been described as potential enzyme inhibitors.⁶ For example, 3,4-dehydro-L-proline is an effective inhibitor of proline dehydrogenase.⁷


Simple syntheses of new α,α -disubstituted amino acids, containing α -alkynyl and α -CF₃ groups, are of interest as proline derivative precursors. As ruthenium-allenylidene complexes of the type (LnRu=C=C=CR₂)⁺PF₆[–] were recently shown to be excellent catalyst precursors for enyne metathesis in the synthesis of dihydrofuran derivatives,⁸ it might be expected that α -alkynyl, α -CF₃ α -amino esters could offer a direct access to unsaturated cyclic amino esters, and especially to unsaturated proline analogs.

We now report (i) general access to a variety of α -CF₃ α -alkynyl amino esters from the readily available electrophilic imines (CF₃)(CO₂Me)C=N–R and (ii) their use for access to 5-membered ring, fluorinated amino esters *via* enyne metathesis performed with the ruthenium-allenylidene precatalyst

[Ru=C=C=CR₂(Cl)(PCy₃)(*p*-cymene)]⁺CF₃SO₃[–] [eqn. (1)].




Electrophilic α -CF₃, α -CO₂Me imines constitute excellent starting materials for the formation of bifunctional α -CF₃ α -amino esters.⁹ The starting electrophilic imines **2a** and **2b** were prepared in quantitative yields (90–95%) from the fluorinated keto ester CF₃COCO₂Me, **1**,¹⁰ upon addition of H₂Nt, H₂NSO₂Ph or H₂NCbz, followed by dehydration¹¹ (Scheme 1). The addition of lithium acetylide to an imine **2**, followed by hydrolysis,¹² led to the new α -CF₃, α -alkynyl amino esters **3**. The treatment of the amino esters **3** with NaH, followed by allyl bromide addition in DMF, afforded α -CF₃ amino esters **4** with the 1,6-enyne structure (Scheme 1). Thus, the derivatives **4a** (R = H), **4b** (R = Buⁿ), **4c** (R = CH₂OMe), **4d** (R = cyclopropyl) and **4e** [R = C(Me)=CH₂] were obtained in overall yields of 40, 42, 60, 50 and 28%, respectively, directly from the imines **2a–c** without purification of the intermediates **3**. Similarly, the α -CF₂Cl-containing imine CF₂Cl(CO₂Me)C=N–Boc, **2d**,¹³ led to the new α -alkynyl-*N*-allyl amino ester **5** [eqn. (2)].




The catalytic enyne metathesis on the fluorinated enynes **4** was then attempted. A solution of the α -CF₃ amino ester **4a** (0.2 mmol) in toluene (5 mL) with 10 mol.% of catalyst [Ru=C=C=CPh₂(Cl)(PCy₃)(*p*-cymene)]⁺PF₆[–], **A**,^{14,15} was irradiated at 300 nm for 0.5 h at room temperature and then the mixture was heated at 80 °C for 69 h in order to reach 90% conversion of **4a**. The 5-membered cyclic amino ester **6** resulting from enyne metathesis was isolated in 70% yield (Scheme 2). Thus, the catalyst **A** appears to be less active towards the bulky enynes **4** than in the enyne metathesis of smaller mixed propargyl allyl ethers to give dihydrofurans.⁸ The reaction of **4a** was then performed with 5 mol.% of the

† Dedicated to the memory of Professor Olivier Kahn



Scheme 1 Reagents and conditions: (i) H₂N-PG [H₂NTs or H₂NSO₂Ph (without solvent) or H₂NBoc or H₂NCbz (both in dichloromethane)]; (ii) SOCl₂ in excess (> 5 equiv.) with a catalytic amount of pyridine for PG = Ts or SO₂Ph; (iii) 1 equiv. of trifluoroacetic anhydride (TFAA), 2 equiv. of pyridine for PG = Cbz or Boc; (iv) 1 equiv. of R-C≡CLi in THF and then hydrolysis; (v) 2 equiv. of NaH and then allyl bromide (3 equiv.) in DMF.



Scheme 2


salt catalyst, but with a different counter anion, [Ru=C=C=Ph₂(Cl)(PCy₃)(*p*-cymene)]⁺CF₃SO₃[−], **B**.^{15,16} After irradiation for 0.5 h at room temperature, only 24 h of heating in toluene at 80 °C led to 95% conversion of **4a** and to the isolation of **6** in 58% yield. Thus, the triflate catalyst **B** appeared to tolerate the CF₃ group as well, brought the best compromise for this enyne metathesis and was selected for further use.

Catalyst **B** is easily prepared *in situ*, just before use for the transformation of 0.2 mmol of enyne, from 14 mg (2 × 10^{−2} mmol) of the very stable salt [RuCl(PCy₃)(*p*-cymene)]⁺TfO[−], **C**,¹⁶ and 4 mg of HC≡C-CPh₂OH (1 equiv.) in 2 mL of toluene. After 30 min of stirring at room temperature, the enyne (0.2 mmol) was then introduced and the enyne metathesis performed as described above. The stable salt **C** simply results from the quantitative one-pot transformation of the commercial precursor [RuCl₂(*p*-cymene)]₂ on addition of 1 equiv. of PCy₃, to produce RuCl₂(PCy₃)(*p*-cymene),¹⁶ followed by the reaction with 1 equiv. of AgOTf. The metathesis of enynes **4b** and **4c**, containing a disubstituted C≡C bond, required more forcing conditions. Enyne **4b** (0.2 mmol) with 10 mol.% of catalyst **B** in toluene, after 0.5 h UV irradiation followed by 4 days at 80 °C, led to 86% conversion and 40% of isolated derivative **7**. Analogously, after 3 days at 80 °C, **4c** led to 48% conversion into **8** isolated in 14% yield (Scheme 2).

In contrast, the novel cyclopropyl (**4d**) and isopropenyl (**4e**) derivatives were not transformed under these conditions. This is likely due to the bulkiness of the cyclopropyl and isopropenyl groups, since the C≡C bond is expected to initially interact with the catalyst.¹⁷ The N-Boc-protected α-CF₂Cl enyne **5** containing the α-HC≡C group is transformed under similar conditions as for **4a** (5 mol.% of **B**, 0.5 h irradiation, and 25 h

at 80 °C) to yield the cyclic amino ester **9** (56%) (Scheme 2). The amino esters **6–9** contrast well with the cyclic amino esters obtained *via* alkene metathesis¹⁸ as they contain a diene moiety and are potentially suitable precursors for Diels–Alder reactions. Thus, the diene **6** was refluxed with 3 equiv. of EtO₂CC≡CCO₂Et in toluene for 18 h and the Diels–Alder adduct **10** was isolated in 77% yield, showing the presence of two diastereoisomers in a 7 : 1 ratio. Compound **10** was aromatized on treatment with dichlorodicyanobenzoquinone (DDQ; 5 equiv.). After 24 h of reflux in toluene only 50% of **10** was converted, however, the new fluorine-containing bicyclic amino ester **11** was isolated in 37% yield (Scheme 3).

The above reactions show that the ruthenium-allenylidene complex **B** is a useful catalyst for access to bicyclic amino esters.



Scheme 3

Experimental

General procedure for the preparation of **3**

The imine **2** (5 mmol) in dry THF (15 ml) was added dropwise to a stirred solution of 6 mmol of lithium acetylide at −78 °C. After 1 h at −78 °C the reaction mixture was allowed to warm up to room temperature and stirred for 5 h. The reaction was quenched with a saturated solution of NH₄Cl and extracted with diethyl ether (2 × 20 ml). The organic layer was washed with brine (25 ml), dried over MgSO₄ and filtered. The solvent was removed under reduced pressure and the crude product, characterized by ¹H NMR, was used directly without purification.

General procedure for the preparation of 4 and 5

A solution of **3** (3 mmol) in dry DMF (9 ml) was added to a suspension of NaH (6 mmol) in dry DMF (15 ml) at 0 °C. The mixture was stirred at room temperature for 0.5 h and then 9 mmol of allyl bromide (in solution in 6 ml of DMF) were added. After stirring for an additional 5 h, the mixture was hydrolyzed with water (20 ml) and extracted with diethyl ether (2 × 20 ml). The organic layer was washed with water (4 × 20 ml), dried over MgSO₄ and filtered. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (diethyl ether–pentane). Compounds **4a–e** and **5** were characterized by ¹H, ¹³C and ¹⁹F NMR and gave satisfactory elemental analyses.

4a. ¹H NMR (CDCl₃, 200.132 MHz): δ 2.75 (s, 1 H, C=CH), 3.97 (s, 3 H, OCH₃), 4.00–4.27 (m, 2 H, CH₂N), 4.87 (dm, 1 H, ³J = 10.1, *cis*-CH₂=CH), 4.94 (dm, 1 H, ³J = 16.9 Hz, *trans*-CH₂=CH), 5.52–5.74 (m, 1 H, CH₂=CH), 7.44–7.65 (m, 3 H, Ph), 7.88–7.97 (m, 2 H, Ph). ¹⁹F NMR (CDCl₃, 188.292 MHz): δ –71.9 (s, 3 F, CF₃). ¹³C NMR (CDCl₃, 50.329 MHz): δ 50.60 (NCH₂), 54.35 (OCH₃), 72.59 (quat. C), 80.15 (C=CH), 97.95 (C≡CH), 117.44 (CH₂=CH), 122.39 (q, ¹J_{CF} = 288.7 Hz, CF₃), 128.65, 128.99, 133.60 (aromatic CH), 133.48 (CH₂=CH), 139.22 (*ipso* C), 163.294 (C=O). Anal. found: C, 49.29; H, 3.68%. Calc. for C₁₅H₁₄F₃NO₄S: C, 49.86; H, 3.90%.

5. ¹H NMR (CDCl₃, 200.132 MHz): δ 1.39 (s, 9 H, 3 × CH₃ Boc), 2.72 (s, 1 H, C=CH), 3.83 (s, 3 H, OCH₃), 4.10–4.25 (m, 2 H, CH₂N), 5.13 (dm, 1 H, ³J = 10.2, *cis*-CH₂=CH), 5.25 (dm, 1 H, ³J = 17.2 Hz, *trans*-CH₂=CH), 5.76–6.04 (m, 1 H, CH₂=CH). ¹³C NMR (CDCl₃, 50.329 MHz): δ 28.00 (3 × CH₃ Boc), 50.22 (NCH₂), 53.45 (OCH₃), 73.93 (quat. CCF₂Cl), 79.14 (C=CH), 82.45 [C(CH₃)₃], 97.86 (C≡CH), 116.19 (CH₂=CH), 128.06 (t, ¹J_{CF} = 288.6 Hz, CF₂Cl), 134.25 (CH₂=CH), 152.58 (C=O Boc), 163.23 (C=O).

General procedure for the preparation of 6–9

A mixture of enyne **4** or **5** (1 mmol) and catalyst **A** or **B** (5 or 10 mol.%) in toluene was irradiated at room temperature for 0.5 h and then heated at 80 °C. The solvent was removed in vacuum and the crude product was purified by flash chromatography (diethyl ether–pentane). Compounds **6–9** were characterized by ¹H, ¹³C and ¹⁹F NMR and gave satisfactory elemental analyses.

6. ¹H NMR (CDCl₃, 200.132 MHz): δ 3.87 (s, 3 H, OCH₃), 4.03 (d, 1 H, ³J = 14.8, CH₂N), 4.53 (d, 1 H, ³J = 14.8, CH₂N), 5.21 (d, 1 H, ³J = 11.4, *cis*-CH₂=CH), 5.47 (d, 1 H, ³J = 17.6, *trans*-CH₂=CH), 6.12 (dd, 1 H, ³J = 11.4, ³J = 17.7 Hz, CH₂=CH), 6.19–6.27 (m, 1 H, CH₂CH=C), 7.43–7.65 (m, 3 H, Ph), 7.82–7.93 (m, 2 H, Ph). ¹⁹F NMR (CDCl₃, 188.292 MHz): δ –71.9 (s, 3 F, CF₃). ¹³C NMR (CDCl₃, 50.329 MHz): δ 53.53 (OCH₃), 55.02 (CH₂N), 68.02 (CCF₃), 119.16 (CH₂=CH), 123.40 (q, ¹J_{CF} = 287.4 Hz, CF₃), 126.71 (CH₂CH=), 128.58 (CH₂=CH), 127.40, 129.07, 133.22 (aromatic CH), 135.40 (quat. C=), 139.51 (*ipso* C), 165.65 (C=O). Anal. found: C, 49.71; H, 4.17%. Calc. for C₁₅H₁₄F₃NO₄S: C, 49.86; H, 3.90%.

Characterization of 10 and 11

10 (major diastereoisomer). ¹H NMR (CDCl₃, 200.132 MHz): δ 1.25 (t, 3 H, ³J = 7.1, CH₃CH₂), 1.29 (t, 3 H, ³J = 7.1 Hz, CH₃CH₂), 3.06–3.20 (m, 1 H, =CHCH₂), 3.50–3.64 (m, 1 H, =CHCH₂), 3.84 (m, 3 H, CH₂N and CHCH₂N), 5.88 (m, 1 H, CH₂CH=), 7.40–7.62 (m, 3 H, Ph), 7.79–7.91 (m, 2 H, Ph). ¹⁹F NMR (CDCl₃, 282.408 MHz): δ –71.62 (s, 3 F, CF₃). ¹³C NMR (CDCl₃, 50.329 MHz): δ 13.83 (CH₃CH₂), 14.00 (CH₃CH₂), 29.71 (CH₂CH=), 38.35 (CHCH₂N), 52.48

(CH₂N), 53.43 (OCH₃), 61.78 (CH₃CH₂), 62.71 (CH₃CH₂), 72.79 (q, ²J_{CF} = 29.7, CCF₃), 122.21 (CH₂CH=C), 128.43 (q, ¹J_{CF} = 285.5 Hz, CF₃), 127.26, 129.15, 133.33 (aromatic CH), 133.83 [CH₂C(CO)=C], 135.60 (*ipso* C), 139.85 [CHC(CO)=C], 165.70 (quat. CH=C), 164.87, 166.39, 167.21 (C=O).

11. ¹H NMR (CDCl₃, 200.132 MHz): δ 1.33 (t, 3 H, ³J = 7.1, CH₃CH₂), 1.34 (t, 3 H, ³J = 7.1, CH₃CH₂), 3.83 (s, 3 H, OCH₃), 4.34 (q, 2 H, ³J = 7.1, CH₃CH₂), 4.35 (q, 2 H, ³J = 7.1, CH₃CH₂), 4.69 (d, 1 H, ²J = 14.4, CH₂N), 5.18 (d, 1 H, ²J = 14.4, CH₂N), 7.44–7.61 (m, 4 H, aromatic H), 7.71 (d, 1 H, ³J = 7.71 Hz, aromatic H), 7.88–7.98 (m, 2 H, aromatic H). ¹⁹F NMR (CDCl₃, 282.408 MHz): δ –72.51 (s, 3 F, CF₃). ¹³C NMR (CDCl₃, 50.329 MHz): δ 14.04 (CH₃CH₂), 14.12 (CH₃CH₂), 53.78 (OCH₃), 54.48 (CH₂N), 62.20 (CH₃CH₂), 62.32 (CH₃CH₂), 72.95 (CCF₃), 126.02, 127.47, 129.23, 133.32, 133.50 (aromatic C), 128.6, 134.77 (quat. aromatic C, CC=O), 132.7 (q, ¹J_{CF} = 283.0 Hz, CF₃), 128.60, 136.60, 138.53, 139.22 (quat. aromatic C), 165.44, 165.72, 166.61 (C=O).

Acknowledgements

The authors wish to thank the European Union INTAS programme 97-1874 for support, the COST programme D12/0025/99 and the Region Bretagne for a grant to J. LN.

References

- 1 For a review see: H. Heimgartner, *Angew. Chem., Int. Ed. Engl.*, 1991, **30**, 238.
- 2 C. Tomiolo, M. Crisma, S. Pegoraro, E. L. Becker, S. Polinelli, W. H. J. Boesten, H. E. Schoemaker, E. M. Meijer, J. Kamphuis and R. Freer, *Peptide Res.*, 1991, **4**, 66.
- 3 C. Walsh, *Tetrahedron*, 1982, **38**, 871 and references cited therein.
- 4 (a) Y. Kuroda, M. Okuhara, T. Goto, E. Iguchi, M. Kohsaka, H. Aoki and H. Imanaka, *J. Antibiot.*, 1980, **33**, 125; (b) D. Schirlin, J. B. Ducep, S. Baltzer, P. Bey, F. Piriou, J. Wagner, J. M. Hornsperger, J. G. Heydt, M. J. Jung, C. Danzig, R. Weiss, J. Fischer, A. Mitschler and A. De Cian, *J. Chem. Soc., Perkin Trans. 1*, 1992, 1053.
- 5 (a) D. J. Barlow and J. M. Thornton, *J. Mol. Biol.*, 1988, **201**, 601; (b) A. M. Koskinen and H. Rapoport, *J. Org. Chem.*, 1989, **54**, 1859; (c) H. H. Ibrahim and W. D. Lubell, *J. Org. Chem.*, 1993, **58**, 6438.
- 6 (a) D. O. Gray and L. Fowden, *Nature (London)*, 1962, **193**, 1285; (b) D. O. Gray and L. Fowden, *Phytochemistry*, 1972, **11**, 745.
- 7 F. Manfre, J.-M. Kern and J.-F. Biellmann, *J. Org. Chem.*, 1992, **57**, 2060.
- 8 M. Picquet, C. Bruneau and P. H. Dixneuf, *Chem. Commun.*, 1998, 2249.
- 9 N. Sewald and K. Burger, in *Fluorine-containing Amino Acids: Synthesis and Properties*, ed. V. P. Kukhar and V. A. Soloshonok, Wiley, Chichester, UK, 1995, p. 139, and references cited therein.
- 10 I. L. Knunyants, V. V. Shokina and V. V. Tyuleneva, *Dokl. Akad. Nauk SSSR*, 1966, **169**, 594; I. L. Knunyants, V. V. Shokina and V. V. Tyuleneva, *Chem. Abs.*, 1966, **65**, 15218e.
- 11 (a) S. N. Osipov, N. D. Chkanikov, A. F. Kolomiets and A. V. Fokin, *Bull. Acad. Sci. USSR, Div. Chem. Sci. (Engl. Transl.)*, 1986, 1256; (b) K. Burger, E. Hoess, K. Gaa, N. Sewald and C. Schierlinger, *Z. Naturforsch. B*, 1991, **46**, 361; (c) S. N. Osipov and K. Burger, *Tetrahedron Lett.*, 2000, **41**, 5659.
- 12 The protocol described for analogous compounds in K. Burger and N. Sewald, *Synthesis*, 1990, 115 was used.
- 13 S. N. Osipov, A. S. Golubev, N. Sewald, T. Michel, A. F. Kolomiets, A. V. Fokin and K. Burger, *J. Org. Chem.*, 1996, **61**, 7521.
- 14 A. Fürstner, M. Picquet, C. Bruneau and P. H. Dixneuf, *Chem. Commun.*, 1998, 1315.
- 15 A. Fürstner, M. Liebl, C. W. Lehmann, M. Picquet, R. Kunz, C. Bruneau, D. Touchard and P. H. Dixneuf, *Chem. Eur. J.*, 2000, **6**, 1847.
- 16 M. Picquet, D. Touchard, C. Bruneau and P. H. Dixneuf, *New J. Chem.*, 1999, **23**, 141.
- 17 (a) T. J. Katz and T. M. Sivavec, *J. Am. Chem. Soc.*, 1985, **107**, 737; (b) T. M. Sivavec, T. J. Katz, M. Y. Chiang and G. X.-Q. Yang, *Organometallics*, 1989, **8**, 1620.
- 18 S. Osipov, C. Bruneau, M. Picquet, A. F. Kolomiets and P. H. Dixneuf, *Chem. Commun.*, 1998, 2053.